Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker “MACK."The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.
